PMID- 30133055
OWN - NLM
STAT- MEDLINE
DCOM- 20181012
LR  - 20210109
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 109
IP  - 10
DP  - 2018 Oct
TI  - Prognostic impact of the tumor immune microenvironment in synovial sarcoma.
PG  - 3043-3054
LID - 10.1111/cas.13769 [doi]
AB  - The association between the immune status within the tumor microenvironment and 
      prognosis in synovial sarcoma is not well understood. We aimed to investigate the 
      tumor immune microenvironment and analyze its prognostic impact for patients with 
      synovial sarcoma. A total of 36 primary patients who were treated in our 
      institution were retrospectively evaluated. Infiltration of lymphocytes (CD4+, 
      CD8+, and FOXP3+), CD163+ macrophages, and expression of human leukocyte antigen 
      (HLA) class I and programmed death ligand 1 (PD-L1) were evaluated by 
      immunohistochemistry. Moreover, we investigated PD-L1 and programmed death ligand 
      2 (PD-L2) mRNA expression in 19 of the 36 cases, using real-time PCR. The 
      Kaplan-Meier method was used to estimate overall survival and progression-free 
      survival. Infiltration of lymphocytes and macrophages varied among the patients. 
      Furthermore, the expression of HLA class I was negative or downregulated in 11 
      specimens. No PD-L1 expression was observed using immunohistochemistry. Moreover, 
      although PD-L1 mRNA expression was observed in 18 of 19 specimens, the expression 
      level was low. A higher infiltration of CD8+ or FOXP3+ lymphocytes in patients 
      was associated with a favorable overall survival. In addition, a higher 
      infiltration of CD163+ macrophages indicated a significantly worse overall and 
      progression-free survival. Infiltration of CD4+ lymphocytes, HLA class I, PD-L1, 
      and PD-L2 expression were not associated with patient prognosis. This represents 
      the first report investigating the tumor immune microenvironment as a prognostic 
      factor in synovial sarcoma, indicating that CD163+ macrophages are associated 
      with tumor progression. Our results underscore the clinical significance of the 
      tumor immune microenvironment in synovial sarcoma.
CI  - (c) 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Oike, Naoki
AU  - Oike N
AUID- ORCID: 0000-0003-3067-392X
AD  - Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, 
      Niigata University, Niigata, Japan.
FAU - Kawashima, Hiroyuki
AU  - Kawashima H
AD  - Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, 
      Niigata University, Niigata, Japan.
FAU - Ogose, Akira
AU  - Ogose A
AD  - Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, 
      Niigata University, Niigata, Japan.
AD  - Department of Orthopedic Surgery, Uonuma Kikan Hospital, Niigata, Japan.
FAU - Hotta, Tetsuo
AU  - Hotta T
AD  - Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, 
      Niigata University, Niigata, Japan.
FAU - Hatano, Hiroshi
AU  - Hatano H
AD  - Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
FAU - Ariizumi, Takashi
AU  - Ariizumi T
AD  - Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, 
      Niigata University, Niigata, Japan.
FAU - Sasaki, Taro
AU  - Sasaki T
AD  - Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
FAU - Yamagishi, Tetsuro
AU  - Yamagishi T
AD  - Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, 
      Niigata University, Niigata, Japan.
FAU - Umezu, Hajime
AU  - Umezu H
AD  - Department of Pathology, Graduate School of Medical and Dental Sciences, Niigata 
      University, Niigata, Japan.
FAU - Endo, Naoto
AU  - Endo N
AD  - Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, 
      Niigata University, Niigata, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180916
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD274 protein, human)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - B7-H1 Antigen/immunology/metabolism
MH  - Biomarkers, Tumor/*immunology
MH  - Biopsy
MH  - Cell Line, Tumor
MH  - Child
MH  - Disease-Free Survival
MH  - Female
MH  - Histocompatibility Antigens Class I/immunology/metabolism
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Macrophages/*immunology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Sarcoma, Synovial/*immunology/mortality/pathology/surgery
MH  - Tumor Microenvironment/*immunology
MH  - Young Adult
PMC - PMC6172059
OTO - NOTNLM
OT  - CD163+ macrophage
OT  - prognosis
OT  - programmed death ligand 1
OT  - synovial sarcoma
OT  - tumor immune microenvironment
EDAT- 2018/08/23 06:00
MHDA- 2018/10/13 06:00
PMCR- 2018/10/01
CRDT- 2018/08/23 06:00
PHST- 2018/05/01 00:00 [received]
PHST- 2018/08/07 00:00 [revised]
PHST- 2018/08/08 00:00 [accepted]
PHST- 2018/08/23 06:00 [pubmed]
PHST- 2018/10/13 06:00 [medline]
PHST- 2018/08/23 06:00 [entrez]
PHST- 2018/10/01 00:00 [pmc-release]
AID - CAS13769 [pii]
AID - 10.1111/cas.13769 [doi]
PST - ppublish
SO  - Cancer Sci. 2018 Oct;109(10):3043-3054. doi: 10.1111/cas.13769. Epub 2018 Sep 16.